Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
2.70
Dollar change
-0.37
Percentage change
-12.05
%
Index- P/E- EPS (ttm)-0.41 Insider Own2.46% Shs Outstand5.45M Perf Week13.45%
Market Cap14.72M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float5.31M Perf Month219.45%
Income-2.25M PEG- EPS next Q- Inst Own4.39% Short Float0.04% Perf Quarter145.45%
Sales0.00M P/S- EPS this Y- Inst Trans-1.10% Short Ratio0.00 Perf Half Y246.11%
Book/sh0.46 P/B5.88 EPS next Y- ROA-59.42% Short Interest0.00M Perf Year159.62%
Cash/sh0.41 P/C6.66 EPS next 5Y- ROE-62.00% 52W Range0.75 - 4.99 Perf YTD167.30%
Dividend Est.- P/FCF- EPS past 5Y-4.31% ROI-89.80% 52W High-45.89% Beta1.10
Dividend TTM- Quick Ratio14.09 Sales past 5Y0.00% Gross Margin- 52W Low260.00% ATR (14)0.43
Dividend Ex-Date- Current Ratio14.09 EPS Y/Y TTM-244.06% Oper. Margin0.00% RSI (14)75.69 Volatility35.46% 20.48%
Employees8 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price6.00
Option/ShortNo / No LT Debt/Eq0.00 EPS Q/Q74.17% Payout- Rel Volume0.57 Prev Close3.07
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume890.95K Price2.70
SMA2099.26% SMA50148.72% SMA200157.45% Trades Volume506,105 Change-12.05%
Date Action Analyst Rating Change Price Target Change
May-08-15Initiated H.C. Wainwright Buy $6
Mar-20-24 10:15AM
Oct-20-23 04:00PM
04:00PM
Nov-21-18 08:00AM
Nov-01-18 10:09AM
09:09AM Loading…
Jul-24-18 09:09AM
May-29-18 05:37PM
Dec-13-17 07:30AM
Dec-06-17 12:08PM
Nov-27-17 10:30AM
Oct-23-17 11:23AM
Oct-06-17 07:30AM
Oct-05-17 07:50AM
Sep-26-17 09:23AM
Sep-12-17 09:00AM
07:00AM Loading…
Jul-11-17 07:00AM
Jun-15-17 09:00AM
Apr-27-17 09:50AM
Apr-05-17 09:10AM
Mar-30-17 08:55AM
Mar-22-17 09:22AM
Mar-07-17 12:40PM
Mar-01-17 08:30AM
Feb-17-17 08:00AM
Feb-13-17 09:08AM
Jan-25-17 08:30AM
Jan-05-17 08:30AM
Dec-19-16 08:00AM
Dec-06-16 08:30AM
Nov-09-16 01:25PM
08:30AM Loading…
Sep-27-16 08:30AM
Sep-07-16 08:32AM
Sep-06-16 08:00AM
Aug-11-16 09:00AM
Jun-02-16 09:11AM
Jun-01-16 08:30AM
May-16-16 11:45AM
Apr-07-16 01:04PM
Mar-31-16 09:45AM
Mar-21-16 08:30AM
Mar-09-16 08:29AM
Mar-02-16 09:00AM
Feb-22-16 09:02AM
Feb-10-16 08:30AM
Jan-27-16 08:30AM
Jan-25-16 08:30AM
Jan-13-16 08:30AM
Jan-11-16 08:30AM
Dec-01-15 08:30AM
Nov-09-15 08:30AM
Oct-28-15 09:00AM
Oct-26-15 09:15AM
Oct-13-15 08:45AM
Sep-17-15 11:40AM
Sep-03-15 09:00AM
Sep-01-15 09:00AM
Aug-26-15 09:00AM
Jun-01-15 08:00AM
May-11-15 10:50AM
May-09-15 09:45AM
May-08-15 09:35AM
07:43AM
Apr-28-15 07:45AM
Mar-31-15 09:30AM
Feb-17-15 08:30AM
Dec-30-14 12:23PM
Dec-08-14 08:30AM
Dec-01-14 08:00AM
Sep-02-14 12:09PM
Jul-22-14 02:54PM
Jul-16-14 09:18AM
Jun-12-14 08:00AM
Jun-02-14 09:00AM
May-19-14 08:00AM
Apr-02-14 04:41PM
Mar-25-14 08:00AM
Jan-08-14 08:00AM
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.